Key result
Dapagliflozin improves cardiac structure, function, and biomarkers in diabetic patients with preserved EF.
Why the study?
Does dapagliflozin improve cardiac function and structure in diabetic patients with preserved ejection fraction?
Does dapagliflozin improve cardiac function and structure in diabetic patients with preserved ejection fraction?
Dapagliflozin is associated with improvements in surrogate echocardiographic and biomarker profiles of cardiac structure and function in diabetic patients with preserved ejection fraction.
Supports surrogate benefits in diabetic HFpEF; hypothesis-generating and requires RCTs before practice change.
= 0.05). Moreover, dapagliflozin decreased the levels of plasma creatin-kinase (CK-MB) and atrial natriuretic peptide (ANP). In conclusion, our data show that the use of SGLT2i is associated with both structural (myocardial mass) and functional (IVRT, LV-GLS) cardiac improvements in a population of diabetic patients with normal ejection fraction.
No takes yet. Share an insight, caveat, or question.
Cortés et al. (2023) studied this question. Dapagliflozin improved structural and functional cardiac parameters (myocardial mass, IVRT, LV-GLS) and decreased ANP and CK-MB in diabetic patients with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: